Information  X 
Enter a valid email address

Synairgen plc (SNG)

  Print      Mail a friend       Annual reports

Friday 16 October, 2020

Synairgen plc

Exercise of Options and Total Voting Rights

RNS Number : 3775C
Synairgen plc
16 October 2020


Synairgen plc

("Synairgen" or the "Company")


Exercise of Options and Total Voting Rights


Southampton, UK - 16 October 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that the Company has applied for a total of 16,462 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") to be issued and allotted pursuant to the exercise of options by Dr Victoria Tear, PDMR.

The Ordinary Shares were exercised at a price of 1 pence by Dr Victoria Tear and subsequent to this, the Company was notified on 16 October that on that same day, Dr Victoria Tear sold 8,367 Ordinary Shares at a price of 195.5 pence per Ordinary Share to meet subscription and taxation costs.

As a result of the exercise of options, application has been made for the 16,462 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on or around 22 October 2020.

The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued share capital will consist of 165,104,676 Ordinary Shares. Accordingly, the figure of 165,104,676 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.



Synairgen plc                                                                                                            +44 (0) 23 8051 2800

Richard Marsden (Chief Executive Officer)

John Ward (Finance Director)

finnCap - Nominated Adviser and Joint Broker  +44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)

Alice Lane / Sunila de Silva (ECM)

Numis - Joint Broker                                                                                                +44 (0) 20 7260 1000

James Black / Freddie Barnfield / Duncan Monteith

Consilium Strategic Communications - Financial Media and Investor          +44 (0) 20 3709 5700

Relations Adviser

Mary-Jane Elliott / Sue Stuart / Olivia Manser


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.



About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma, COPD and COVID-19, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see





Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')



Dr Victoria Tear


Reason for notification


Position / status

Head of Laboratories, PDMR of the Company


Initial notification / amendment

Initial Notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Synairgen plc





Details of the transaction(s):


Description of the financial instrument

Identification code

O ptions over o rdinary shares of 1p each



Nature of the transaction

Exercise of options over Ordinary Shares; and

Sale of Ordinary Shares of 1p each



Price(s) and volume(s)





Exercise of Options



Sale of Ordinary Shares






Aggregated information

Aggregated volume Price



Date of the transaction

16 October 2020


Place of the transaction

London Stock Exchange




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t